Search alternatives:
larger decrease » marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
Showing 401 - 420 results of 4,639 for search 'significantly ((((((larger decrease) OR (linear decrease))) OR (nn decrease))) OR (mean decrease))', query time: 0.28s Refine Results
  1. 401
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 402
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 403
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 404
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 405
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 406
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 407
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 408
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 409
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 410
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 411
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 412
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 413
    Spearman’s correlation coefficients between mean scores of each S-Hab-Q factor and the AQ subscales.

    Spearman’s correlation coefficients between mean scores of each S-Hab-Q factor and the AQ subscales. by Vincenza Tarantino (182506)

    Published 2024
    Save to List
    Saved in:
  14. 414
    Puriton had the tendency of decreasing expressions of Th1 cell-related cytokines such as IFN-

    Puriton had the tendency of decreasing expressions of Th1 cell-related cytokines such as IFN- by So-Hyeon Bok (8066696)

    Published 2025
    Save to List
    Saved in:
  15. 415
    Forest plots illustrate the mean difference in; (A) creatinine clearance, (B) eGFR, (C) BUN, and (D) shows relative risk in ARF.

    Forest plots illustrate the mean difference in; (A) creatinine clearance, (B) eGFR, (C) BUN, and (D) shows relative risk in ARF. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    Save to List
    Saved in:
  16. 416
    Change in Watt’s Connectedness Scale, Subscales by Treatment Group.

    Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 417
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 418
    Demographic and clinical characteristics of participants at baseline.

    Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 419
    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group.

    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 420
    Change in Demoralization Scale (DSII) by Treatment Group.

    Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: